Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty-seven ratings firms that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $133.65.
Several research analysts have recently commented on the company. Jefferies Group reiterated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $120.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Gabelli began coverage on Zimmer Biomet in a research note on Thursday, August 24th. They set a “buy” rating and a $142.00 target price for the company. SunTrust Banks restated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Monday, October 2nd. Finally, TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th.
Zimmer Biomet (NYSE:ZBH) opened at $113.38 on Monday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a one year low of $100.81 and a one year high of $133.49. The company has a market capitalization of $22,956.39, a P/E ratio of 14.05, a PEG ratio of 1.76 and a beta of 1.15.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the prior year, the firm posted $1.79 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. research analysts anticipate that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. AXA raised its holdings in Zimmer Biomet by 26.3% in the 3rd quarter. AXA now owns 412,845 shares of the medical equipment provider’s stock valued at $48,340,000 after acquiring an additional 85,861 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in Zimmer Biomet in the 3rd quarter valued at $140,000. Jana Partners LLC raised its holdings in Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after acquiring an additional 662,497 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in Zimmer Biomet by 1.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 86,959 shares of the medical equipment provider’s stock valued at $10,182,000 after acquiring an additional 1,131 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its holdings in Zimmer Biomet by 20.0% in the 3rd quarter. Iguana Healthcare Management LLC now owns 30,000 shares of the medical equipment provider’s stock valued at $3,513,000 after acquiring an additional 5,000 shares in the last quarter. 86.24% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2017/12/11/zimmer-biomet-holdings-inc-zbh-given-average-recommendation-of-hold-by-brokerages.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.